New Five-Year Plan
ROTRF Announces a New Five-Year Plan
Dear Colleagues
Thanks to a further donation from F. Hoffmann-La Roche Ltd, the Roche Organ Transplantation Research Foundation (ROTRF) is pleased to announce a new plan for the coming five years (April 2007 to March 2012).
The ROTRF will continue to fund excellence in research applicable to the understanding and care of human organ transplant recipients and related tissue transplants, such as islet transplantation. The mandate continues to include basic and clinical research, but now increasingly gives priority to investigators who study disease states in patients, or in animal models that simulate the pathology in transplant patients. The mandate will focus on the understanding of the pathogenesis and prevention of human transplantation diseases, including organ injury and rejection, viral infection, and late graft deterioration. Priority will be given to those who can demonstrate that their work focuses on issues relevant to the pathology of organ disease in transplantation.
In practice, this means that an emphasis will be given to research involving transplant patients and material, and to animal and in vitro experiments that can examine aspects of organ transplantation relevant to humans with HLA-incompatible organ transplants. Additionally, the ROTRF will consider funding research that addresses related clinical issues in non-transplant patients, including hepatitis C infection and inflammatory processes relevant to human organ transplantation. These related clinical issues should demonstrate their relevance to disease phenotypes in organ transplant patients. The ROTRF also welcomes research in new emerging technologies examining the pathogenesis of human disease states in organ transplantation.
The Trustees of the ROTRF believe that this is an opportunity to increase focus on the disease mechanisms in human organ transplantation, and to further refine the model systems simulating these disease states.
We are excited about this prospect and grateful to Mr William M. Burns, CEO of the Pharmaceutical Division of Roche Pharmaceuticals of F. Hoffmann-La Roche Ltd, and Dr Jonathan Knowles, President of Group Research of F. Hoffmann-La Roche Ltd, for this continuing support.
back to News >>
(C) 2010, ROTRF, All rights reserved